Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients

Main Article Content

James Del Rosso
Linda Stein Gold
Leon Kircik
Andrew Alexis
Seemal R. Desai
Vassilis Stakias
Iain Stuart

Keywords

Acne Vulgaris, Minocycline, Topical, Efficacy

Abstract

Abstract not available.

References

1. Thiboutot DM, Dreno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2S1):S1-S23.

2. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5)945-973.

3. Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019; 80(1):168-177.

4. Raoof TJ, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2020;82(4):832-837.

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 12 > >>